Nolatrexed, also known as AG337, is a thymidylate synthase inhibitor with potential anticancer activity. A phase II study of nolatrexed in 2007 in advanced HCC patients demonstrated minimal activity and significant stomatitis. Hence, it does not warrant further study as a single agent for this disease.
For research use only. We do not sell to patients.